BOSTON FAMILY OFFICE LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.

Quarter-by-quarter ownership
BOSTON FAMILY OFFICE LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$433
-19.2%
9,5500.0%0.04%
-14.6%
Q2 2023$536
+24.1%
9,5500.0%0.04%
+17.1%
Q1 2023$432
+11.3%
9,5500.0%0.04%
+9.4%
Q4 2022$388
-99.9%
9,5500.0%0.03%
-41.8%
Q3 2022$624,000
+7.6%
9,5500.0%0.06%
+14.6%
Q2 2022$580,000
-3.2%
9,5500.0%0.05%
+11.6%
Q1 2022$599,000
-17.3%
9,5500.0%0.04%
-8.5%
Q4 2021$724,000
-32.3%
9,5500.0%0.05%
-39.0%
Q3 2021$1,069,000
-30.9%
9,5500.0%0.08%
-30.0%
Q2 2021$1,546,000
+32.9%
9,5500.0%0.11%
+26.4%
Q1 2021$1,163,000
-26.3%
9,550
-7.3%
0.09%
-28.1%
Q4 2020$1,577,000
+83.2%
10,3000.0%0.12%
+55.1%
Q3 2020$861,000
+13.7%
10,3000.0%0.08%
+5.4%
Q2 2020$757,000
+73.2%
10,3000.0%0.07%
+42.3%
Q1 2020$437,000
-30.3%
10,3000.0%0.05%
-13.3%
Q4 2019$627,000
+47.2%
10,300
-1.0%
0.06%
+36.4%
Q3 2019$426,000
-13.1%
10,4000.0%0.04%
-13.7%
Q2 2019$490,000
+32.1%
10,4000.0%0.05%
+27.5%
Q1 2019$371,000
+24.9%
10,4000.0%0.04%
+8.1%
Q4 2018$297,000
-36.3%
10,400
-1.0%
0.04%
-24.5%
Q3 2018$466,000
-23.7%
10,500
+1.0%
0.05%
-29.0%
Q2 2018$611,000
+33.7%
10,400
+4.0%
0.07%
+32.7%
Q1 2018$457,00010,0000.05%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2020
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders